down arrow

Mustang Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US62818Q2030
USD
1.32
0.11 (9.09%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.191.33

52 Week

0.8921.95
Valuation
Technical
Day's Volume

CASH

14.1 k

Shareholding (Mar 2025)

FII

0.06%

Held by 6 FIIs

DII

98.93%

Held by 1 DIIs

Promoter

0.00%

How big is Mustang Bio, Inc.?

22-Jun-2025

As of Jun 18, Mustang Bio, Inc. has a market capitalization of 4.47 million, with net sales of 0.00 million and a net profit of -10.71 million over the latest four quarters. The balance sheet shows shareholder's funds of -3.87 million and total assets of 9.31 million.

As of Jun 18, Mustang Bio, Inc. has a market capitalization of 4.47 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -10.71 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of -3.87 million and total assets amounting to 9.31 million.

Read More

What does Mustang Bio, Inc. do?

22-Jun-2025

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on cell and gene therapy for hematologic cancers, solid tumors, and rare genetic diseases. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of $4.47 million and has no recent net sales or profits.

Overview: Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on cell and gene therapy for hematologic cancers, solid tumors, and rare genetic diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>Financial Snapshot: Most recent Net Sales: Not available. Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025). Market-cap: USD 4.47 Million (Micro Cap).<BR><BR>Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: -3.94. Return on Equity: -194.57%. Price to Book: 1.24.<BR><BR>Contact Details: Address: 2 Gansevoort St Fl 9, NEW YORK NY: 10014-1667. Tel: 1 781 6524507. Website: http://www.mustangbio.com/.

Read More

Who are in the management team of Mustang Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Mustang Bio, Inc. includes Executive Chairman Michael Weiss, President and CEO Dr. Manuel Litchman, and Directors Dr. Lindsay Rosenwald, Adam Chill, Neil Herskowitz, and Dr. Michael Zelefsky. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Mustang Bio, Inc. includes the following individuals:<BR><BR>- Mr. Michael Weiss, who serves as the Executive Chairman of the Board.<BR>- Dr. Manuel Litchman, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Lindsay Rosenwald, who is a Director.<BR>- Mr. Adam Chill, who is an Independent Director.<BR>- Mr. Neil Herskowitz, who is also an Independent Director.<BR>- Dr. Michael Zelefsky, who serves as an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Mustang Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Mustang Bio, Inc. has a mildly bearish trend, with mixed technical indicators showing underperformance against the S&P 500, including a year-to-date return of -81.69% compared to the S&P's 12.22%.

As of 8 September 2025, the technical trend for Mustang Bio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. Bollinger Bands indicate a bullish weekly trend but a mildly bearish monthly trend. Moving averages are bearish on the daily, and KST is bullish weekly but bearish monthly. Dow Theory reflects a mildly bullish stance on both time frames, and OBV is mildly bullish weekly and bullish monthly.<BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -81.69% compared to the S&P 500's 12.22%, and a one-year return of -87.24% against the S&P's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-4.38

stock-summary
Return on Equity

-77.25%

stock-summary
Price to Book

3.40

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.29%
0%
-14.29%
6 Months
2.33%
0%
2.33%
1 Year
-85.64%
0%
-85.64%
2 Years
-98.17%
0%
-98.17%
3 Years
164.42%
0%
164.42%
4 Years
-99.91%
0%
-99.91%
5 Years
-99.95%
0%
-99.95%

Mustang Bio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Mustang Bio, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Mustang Bio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. Bollinger Bands indicate a bullish weekly trend but a mildly bearish monthly trend. Moving averages are bearish on the daily, and KST is bullish weekly but bearish monthly. Dow Theory reflects a mildly bullish stance on both time frames, and OBV is mildly bullish weekly and bullish monthly. In terms of performance, the stock has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -81.69% compared to the S&P 500's 12.22%, and a one-year return of -87.24% against the S&P's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
14.24%
EBIT to Interest (avg)
-30.76
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-3.94
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.92%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.50
EV to EBIT
1.13
EV to EBITDA
1.21
EV to Capital Employed
0.83
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
73.41%
ROE (Latest)
-194.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 6 Schemes (1.02%)

Foreign Institutions

Held by 6 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 90.24% vs 49.38% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.90",
          "val2": "-5.60",
          "chgp": "83.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-2.60",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.80",
          "val2": "-8.20",
          "chgp": "90.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 69.38% vs 33.42% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.70",
          "val2": "-48.50",
          "chgp": "75.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.70",
          "val2": "-2.80",
          "chgp": "-32.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.80",
          "val2": "-51.60",
          "chgp": "69.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.90
-5.60
83.93%
Interest
0.00
0.00
Exceptional Items
0.00
-2.60
100.00%
Consolidate Net Profit
-0.80
-8.20
90.24%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 90.24% vs 49.38% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.70
-48.50
75.88%
Interest
0.00
1.30
-100.00%
Exceptional Items
-3.70
-2.80
-32.14%
Consolidate Net Profit
-15.80
-51.60
69.38%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 69.38% vs 33.42% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Mustang Bio, Inc. stock-summary
stock-summary
Mustang Bio, Inc.
Pharmaceuticals & Biotechnology
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company’s pipeline is focused in three areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. MB-107 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency. Its MB-102 is a CD123 CAR T cell Program for acute myeloid leukemia (AML).
Company Coordinates stock-summary
Company Details
2 Gansevoort St Fl 9 , NEW YORK NY : 10014-1667
stock-summary
Tel: 1 781 6524507
stock-summary
http://www.mustangbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."